Sees FY23 Cost of Sales at $420 million to $470 million and R&D expenses at $1.43B to $1.53B
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN:
- Cellectar Biosciences hires Shustov as new Senior Vice President, Medical
- Seagen treatment of esophageal cancer granted orphan designation
- 3 Stocks to Buy Today, 2/13/2023, According to Top Analysts
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- SVB Securities downgrades Seagen to Market Perform, lowers price target to $141